Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]3F-PHPG PET Imaging in Neuroendocrine Tumors
NCT04510311Phase 1Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 3-[18F]fluoro-para-hydroxyphenethylguanidine in Neuroendocrine Neoplasm (NEN) (2 arms), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Image quality assessed by standardized uptake values at 180 months and Biodistribution of [18F]3F-PHPG at 180 months. Started Oct 2020; status: completed.
02
Drugs
3-[18F]fluoro-para-hydroxyphenethylguanidine
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04510311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510311.